Quality of surveillance in patients with completely resected gastroenteropancreatic neuroendocrine tumors.

Authors

Gordon Taylor Moffat

Gordon Taylor Moffat

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

Gordon Taylor Moffat , Aruz Mesci , Sami A. Chadi , Raymond Woo-Jun Jang , Lisa Avery , Carol-Anne Moulton , Paul C. Nathan , Monika K. Krzyzanowska

Organizations

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, University Health Network Toronto, Toronto, ON, Canada, Department of Biostatistics, University Health Network, University of Toronto, Toronto, ON, Canada, Hepatobiliary/Pancreatic Surgical Oncology Program, University Health Network, Toronto, ON, Canada, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada, Division of Medical Oncology & Haematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada

Research Funding

No funding sources reported

Background: The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are increasing worldwide. Surgery remains the only curative modality. Because of limited data on patterns of recurrence, real-world surveillance practices and duration vary widely. In 2018, the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETs) published consensus surveillance guidelines for patients with completely resected GEP-NETs. Our aim was to assess adherence to the CommNETs guidelines for surveillance practices for this patient population at our center. Methods: We conducted a retrospective cohort study of patients with GEP-NETs seen for a new patient appointment at Princess Margaret Cancer Centre (PMCC) from 2019-2022. Patients were included if they had a completely resected GEP-NET and followed on surveillance at our center. Demographic and tumor characteristics, surveillance practices, and clinical outcomes were abstracted. Summary statistics and a descriptive comparison of surveillance practices were completed. Results: Out of the 374 new patient appointments, 87 met the inclusion criteria. The main reasons for exclusion were metastatic disease at presentation (n=128), primary tumor not resected (n=58), and patients not followed at PMCC (n=49) so their surveillance practices cannot be determined from our records. The primary tumor sites were pancreatic (n=50, 57%), appendiceal (n=15, 17%), small bowel (n=11, 13%), rectal (n=10, 12%), and colon (n=1, 1%). Thirty-eight patients (44%) had stage 1 disease, 21 patients (24%) had stage 2, and 28 patients (32%) had stage 3. Forty-six patients (53%) had a WHO tumor grade of 1, 36 patients (41%) had grade 2, and 5 patients (6%) had grade 3. The median duration of follow-up was 18.2 months. Adherence to ordering the recommended surveillance investigations was 23% (20/87). Within the adherent cases, there was a higher number of appendiceal, WHO grade 1, and stage 1 tumors. Sixty-six patients (76%) had at least one test that was not recommended by the guidelines. The most frequent unnecessary tests were CT chest in all patient groups and CT pelvis in pancreatic NETs (Table). Six patients were lost to follow up and none discharged from surveillance. Conclusions: Adherence to the CommNETs consensus guidelines was low at our center, suggesting the guidelines had a minor impact on surveillance practices and providing an area for improvement in process of care and resource utilization.

Number of unnecessary surveillance investigations ordered for 87 patients on surveillance between 2019-2022.

TestTotal Amount
CT Chest111
CT Abdomen40
CT Pelvis119
MRI Abdomen14
MRI Pelvis9
US Abdomen6
Gallium-68-DOTATATE PET Scan2
Chromogranin A33
24-HR Urine 5-HIAA7
Extended Hormonal Testing41
Flexible Sigmoidoscopy3
Colonoscopy7

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Quality of Care/Quality Improvement

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 591)

DOI

10.1200/JCO.2024.42.3_suppl.591

Abstract #

591

Poster Bd #

H2

Abstract Disclosures